Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

ANGECON

company

About

ANGECON focuses on the R&D of cell drugs, healthy cell storage and other fields.

  • 11 - 50

Details

Last Funding Type
Angel
Last Funding Money Raised
¥10M
Industries
Biotechnology,Health Care,Sales
Founded date
Feb 2, 2010
Number Of Employee
11 - 50
Operating Status
Active

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
¥11.18M
ANGECON has raised a total of ¥11.18M in funding over 2 rounds. Their latest funding was raised on Sep 3, 2012 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 3, 2012 Series A ¥1.18M 1 Fudewu Sheng Detail
May 10, 2012 Angel ¥10M 1 Sanjie Touzi Detail

Investors

Number of Lead Investors
Number of Investors
2
2
ANGECON is funded by 2 investors. Fudewu Sheng and Sanjie Touzi are the most recent investors.
Investor Name Lead Investor Funding Round
Fudewu Sheng Yes Series A
Sanjie Touzi Yes Angel